RecruitingPhase 1NCT05452005

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography for Staging, Response Assessment, and Patient Selection in Metastatic Non-Small Cell Lung Cancer

Sponsor

University of California, Davis

Enrollment

20 participants

Start Date

Sep 13, 2022

Study Type

INTERVENTIONAL

Conditions

Lung Cancer Brain Metastases Lung Cancer Metastatic

Summary

This study investigates fluorine-18-AlphaVBeta6-BP (\[18F\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that \[18F\]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new type of PET scan (a special imaging test) that uses a radioactive molecule which binds to a protein called αvβ6 — found on certain cancer cells — to detect cancer that has spread (metastatic disease). The goal is to see how well this new scan finds cancer compared to standard imaging. **You may be eligible if...** - You have metastatic cancer (cancer that has spread from its original location) - Your doctor is evaluating your disease with imaging tests - You are 18 or older and able to undergo a PET scan **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have conditions that prevent you from lying still for the scan - You have severe kidney disease that affects contrast handling - You have claustrophobia severe enough to prevent imaging Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.